login
  Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Medtronic receives FDA approval to treat mildly symptomatic heart failure patients through expanded indication for CRT-D


Tuesday, 10 Apr 2012 10:03

The US Food and Drug Administration (FDA) has approved an expanded indication for Medtronic’s cardiac resynchronisation therapy with implantable cardioverter defibrillator (CRT-D) devices. The approval allows cardiac resyncronisation therapy to be used earlier, in a mildly symptomatic heart failure patient population, potentially improving survival, reducing hospitalisations, and preventing disease progression.


The expanded indication includes New York Heart Association (NYHA) Class II heart failure patients with a left ventricular ejection fraction (LVEF) of less than or equal to 30%, left bundle branch block (LBBB), and a QRS duration greater than or equal to 130 milliseconds. Nearly 200,000 Americans are considered NYHA Class II, with another 620,000 people worldwide fitting this designation. Medtronic CRT-D devices were previously indicated to treat certain patients with moderate-to-severe heart failure (NYHA Class III and IV), and have safely and effectively been used in these patients for more than a decade.


The FDA’s decision for the expanded indication rests on data from the pivotal REVERSE (Resynchronization reverses remodeling in systolic left ventricular dysfunction) and landmark RAFT (Resynchronization/defibrillation in ambulatory heart failure trial) clinical trials, which showed that CRT-D can benefit mildly symptomatic heart failure patients by reducing mortality and heart failure hospitalisation rates.


“The RAFT and REVERSE study findings provide strong clinical evidence validating the safety, efficacy and lifesaving benefits of CRT-D for treating systolic heart failure patients with milder symptoms,” said Michael R Gold, REVERSE study investigator and steering committee member, Michael E Assay professor of medicine and director of cardiology at the Medical University of South Carolina, USA. “This expanded indication fulfills an unmet need by treating these patients in the earlier stages of heart failure, before their symptoms more significantly impact their quality of life.”


While certain NYHA Class II patients are already indicated for an implantable cardioverter defibrillator (ICD) to protect them from sudden cardiac arrest, they are still vulnerable to experiencing an exacerbation of their heart failure. In fact, sudden cardiac arrest is responsible for more than 60% of deaths among patients with mild-to-moderate heart failure. However, a growing body of clinical research suggests that earlier intervention with CRT-D can decrease the risk of morbidity and mortality in this mildly symptomatic patient population.


About the RAFT trial


Findings from the landmark RAFT clinical trial, published in the New England Journal of
Medicine, showed that CRT-D significantly reduced mortality for mildly symptomatic heart failure patients (NYHA Class II) by 29% when compared to patients treated with guideline-recommended implantable ICDs and medical therapy (p=0.006; HR=0.71). The study also demonstrated a significant reduction (27 percent) in combined mortality and heart failure hospitalisations for this population (p=0.001; HR=0.73), consistent with previously published studies. All patients were followed for at least 18 months, and had an average follow-up of 40 months, making it the longest follow-up and largest patient months-of-experience of any study of CRT therapy.


About the REVERSE trial


With 610 patients studied, REVERSE was the first large-scale, global, randomised, double-blind trial to demonstrate the impact of CRT in mild heart failure patients or asymptomatic patients who previously had heart failure symptoms. All randomised subjects received a score of improved, unchanged or worsened, utilising the Clinical Composite Response. For the pre-specified primary endpoint, the results showed that 21% of subjects without CRT worsened, compared to 16% with CRT (p=0.10); however, post-hoc analyses demonstrated that collectively comparing all the classifications of improved, unchanged or worsened was significant (p=0.004).


Importantly, more patients in the trial improved with CRT than without (54% vs. 40%, respectively). Additionally, the analysis of pre-specified secondary endpoints in the REVERSE trial showed that CRT leads to improvement in both cardiac structure and function as measured by echocardiography, meaning the heart size improves and beats more effectively. CRT also delayed the time to first heart failure hospitalisation in this patient group and reduced heart failure hospitalisation or all cause death by 51% (p=0.004, post-hoc).




Add New Comment

Most popular


St Jude Medical completes acquisition of CardioMEMS
Monday, 02 Jun 2014
St Jude Medical has announced it has completed its acquisition of privately held CardioMEMS, developer of the CardioMEMS heart failure system. The acquisition was completed on 30 May 2014. St Jude Medical completes acquisition of CardioMEMS

FDA approves CardioMEMS heart failure system
Monday, 02 Jun 2014
The US Food and Drug Administration has approved the CardioMEMS heart failure system that measures the pulmonary artery pressures and heart rates of patients with New York Heart Association (NYHA) C... FDA approves CardioMEMS heart failure system

Wearable defibrillator registry (WEARIT-II) update
Monday, 23 Jun 2014
At Cardiostim/EHRA Europace (18–21 June, Nice, France), Ilan Goldenberg presented an update on one-year follow-up results from the prospective WEARIT-II registry of 1,404 patients using the Lifevest ... Wearable defibrillator registry (WEARIT-II) update

Features


Is antiarrhythmic gene therapy the future of atrial fibrillation management?
Thursday, 31 Jul 2014
Dierk Thomas (Heidelberg, Germany) writes on the results of preclinical research on antiarrhythmic gene therapy. Is antiarrhythmic gene therapy the future of atrial fibrillation management?

What is the best strategy for managing atrial fibrillation?
Monday, 14 Jul 2014
John D Day, president-elect of the Heart Rhythm Society writes that many cases of atrial fibrillation in the USA could be prevented or reversed with lifestyles focussed on health. What is the best strategy for managing atrial fibrillation?

Profiles


Nick Linker
Monday, 14 Jul 2014
Nick Linker is president-elect of the British Heart Rhythm Society (BHRS) and programme director of ... Nick Linker

Richard Fogel
Thursday, 08 May 2014
Richard Fogel, president-elect of the Heart Rhythm Society and chief executive officer at St V... Richard Fogel

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions